ERBB2 and neoplasm: More recently, in the trial Destiny-CRC02, the antibody-drug conjugate (ADC) trastuzumab-deruxtecan achieved similar results among HER2-positive mCRC patients, including patients previously treated with a HER2-targeted therapy, RAS-mutated, and regardless of primary tumor location [137].